History of the development of antiemetic guidelines at Mayo Clinic Rochester

Mayo Clinic Proceedings

Volumn 75, Issue 3, 2000, Pages 303-309

  Loprinzi, Charles L ^{a,b,c,d,e,f,g,h}   Alberts, Steven R ^a,b   Christensen, Bradley J ^c   Hanson, Lorelei J ^d   Farley, David R ^e   Broers, Joan K ^f   Betcher, Donna L ^g   Grady, Robert E ^h   Southorn, Peter A ^a   Johnson, Todd M ^b   Perez, Edith A ^f  

^a Division of Medical Oncology   (United States)

^b Division of Gastroenterology and Hepatology   (United States)

^c Continuous Improvement ^*  (United States)

^d Department of Anesthesiology ^*  (United States)

^e Hospital Pharmacy Services   (United States)

^f MAYO CLINIC ROCHESTER   (United States)

^g Division of Hematology/Oncology and Internal Medicine   (United States)

^h MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DRONABINOL; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE; PROMETHAZINE; SEROTONIN 3 ANTAGONIST;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE QUALITY; HISTORY OF MEDICINE; HUMAN; NAUSEA; PATIENT SATISFACTION; PRACTICE GUIDELINE; REVIEW; UNITED STATES; VOMITING;

EID: 0034090643     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)65039-8     Document Type: Review

References (35)

1. Soukop M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 1992; 49:295-304.
2. Heron JF, Goedhals L, Jordaan JP, Cunningham J, Cedar E, Granisetron Study Group. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol. 1994;5:579584.
3. Sorbe B, Hogberg T, Himmelmann A, et al. Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. Eur J Cancer. 1994;30A: 629-634.
4. Italian Group of Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol. 1995;6:805-810.
5. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatininduced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991;9:675-678.
6. Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ. 1991;303:1423-1426.
7. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, doubleblind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of highdose cisplatin-induced emesis. J Clin Oncol. 1994; 12:596-600.
8. Joss RA, Bacchi M, Buser K, et al, Swiss Group for Clinical Cancer Research (SAKK). Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapynaive and previously treated patients. Ann Oncol. 1994;5:253-258.
9. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer. 1995;3:307-312.
10. Carmichael J, Bessell EM, Harris AL, Hutcheon AW, Dawes PJ, Daniels S. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis [published correction appears in Br J Cancer. 1995;71:1123]. Br J Cancer. 1994;70:1161-1164.
11. Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet. 1992;340:96-99.
12. Cunningham D, Dicato M, Verweij J, et al. Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondan-setron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Ann Oncol. 1996;7:277-282.
13. Gebbia V, Testa A, Valenza R, Cannata G, Tirrito ML, Gebbia N. Oral granisetron with or without methlyprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy: a prospective randomized trial. Cancer. 1995;76:18211828.
14. Smith DB, Newlands ES, Rustin GJ, et al. A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy. Cancer Chemother Pharmacol. 1990;25:291-294.
15. Gralla RJ, Navari RM, Hesketh PJ, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998;16:1568-1573.
16. Krzakowski M, Graham E, Goedhals L, Pawlicki M, Yelle L, Joly F. Control of acute cisplatin-induced nausea and emesis using a once daily oral treatment regimen of ondansetron plus dexamethasone [abstract]. Eur J Cancer. 1997;33(suppl 8):S19.
17. Kris MG, Pendergrass KB, Navari RM, et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997;15:2135-2138.
18. Nolte MJ, Berkery R, Pizzo B, et al. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1998;16:771-778.
19. Perez EA, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998;16:754-760.
20. Sanchez M, Alvarez I, Paredes A, et al. A double blind randomized placebo-controlled comparison of two maintenance antiemetic regimes in the prevention of delayed cisplatin-induced emesis [abstract]. Ann Oncol. 1994;5(suppl 8):197-198.
21. Greenblatt DJ, Shader RI, Abernathy DR. Drug therapy: current status of benzodiazepines. N EnglJ Med. 1983;309:354-358.
22. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.
23. Roila F, Ballatori E, Contu A, et al. Optimal dose of intravenous (iv) dexamethasone (DEX) in the prevention of cisplatin (CDDP)induced acute emesis: a double-blind randomized study [abstract]. Program P roc Am Soc Clin Oncol. 1998;17:50a.
24. Latreille J, Pater J, Johnston D, et al, National Cancer Institute of Canada Clinical Trials Group. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol. 1998; 16: 1174-1178.
25. Pater JL, Lofters WS, Zee B, et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997;8:181-185.
26. Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol. 1997; 15:124-130.
27. Moreno I, Resell R, Abad A, et al. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatintreated patients. Eur J Cancer. 1992;28A: 1344-1347.
28. Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of an NK, receptor antagonist to prevent delayed emesis after cisplatin [letter]. J Natl Cancer Inst. 1997;89:817-818.
29. Navari RM, Reinhardt RR, Gralla RJ, et al, L-754,030 Antiemetic Trials Group. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med. 1999;340:190195.
30. Philpot CR. Ondansetron by subcutaneous infusion [letter]. Med J Aust. 1993;159:213.
31. Mulvenna PM, Regnard CF. Subcutaneous ondansetron [letter]. Lancet. 1992;339:1059.
32. Wilde MI, Markham A. Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 1996;52:773-794.
33. Currow DC, Coughlan M, Fardell B, Cooney NJ. Use of ondansetron in palliative medicine. J Pain Symptom Manage. 1997;13: 302-307.
34. Porcel JM, Salud A, Porta J, Schoenenberger JA. Antiemetic efficacy of subcutaneous 5-HT3 receptor antagonists in terminal cancer patients [letter]. J Pain Symptom Manage. 1998;15:265-266.
35. NCCN antiemesis practice guidelines. Oncology (Huntingt). 1997; 11:57-89.